vs
OCTAVE SPECIALTY GROUP INC（OSG）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是OCTAVE SPECIALTY GROUP INC的1.0倍（$69.8M vs $66.9M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -73.8%，领先457.8%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 2.6%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 16.2%）
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
OSG vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.0倍
$66.9M
营收增速更快
RIGL
高出18.6%
2.6%
净利率更高
RIGL
高出457.8%
-73.8%
两年增速更快
RIGL
近两年复合增速
16.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.9M | $69.8M |
| 净利润 | $-29.7M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | -76.7% | 33.2% |
| 净利率 | -73.8% | 384.0% |
| 营收同比 | 2.6% | 21.2% |
| 净利润同比 | -41.7% | 1769.2% |
| 每股收益（稀释后） | $-0.82 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OSGRIGL
| Q4 25 | $66.9M | $69.8M | ||
| Q3 25 | $66.6M | $69.5M | ||
| Q2 25 | $55.0M | $101.7M | ||
| Q1 25 | $62.8M | $53.3M | ||
| Q4 24 | $65.2M | $57.6M | ||
| Q3 24 | $70.0M | $55.3M | ||
| Q2 24 | $51.0M | $36.8M | ||
| Q1 24 | $49.6M | $29.5M |
净利润OSGRIGL
| Q4 25 | $-29.7M | $268.1M | ||
| Q3 25 | $-112.6M | $27.9M | ||
| Q2 25 | $-72.7M | $59.6M | ||
| Q1 25 | $-44.7M | $11.4M | ||
| Q4 24 | $-20.9M | $14.3M | ||
| Q3 24 | $-27.5M | $12.4M | ||
| Q2 24 | $-750.0K | $-1.0M | ||
| Q1 24 | $20.8M | $-8.2M |
毛利率OSGRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率OSGRIGL
| Q4 25 | -76.7% | 33.2% | ||
| Q3 25 | -48.2% | 40.9% | ||
| Q2 25 | -41.8% | 60.1% | ||
| Q1 25 | -24.1% | 23.9% | ||
| Q4 24 | -55.5% | 28.9% | ||
| Q3 24 | -29.7% | 25.4% | ||
| Q2 24 | -28.9% | 1.2% | ||
| Q1 24 | -6.5% | -23.6% |
净利率OSGRIGL
| Q4 25 | -73.8% | 384.0% | ||
| Q3 25 | -169.1% | 40.2% | ||
| Q2 25 | -132.3% | 58.6% | ||
| Q1 25 | -71.3% | 21.5% | ||
| Q4 24 | -55.1% | 24.9% | ||
| Q3 24 | -39.3% | 22.5% | ||
| Q2 24 | -1.5% | -2.8% | ||
| Q1 24 | 41.9% | -27.9% |
每股收益（稀释后）OSGRIGL
| Q4 25 | $-0.82 | $14.11 | ||
| Q3 25 | $-2.35 | $1.46 | ||
| Q2 25 | $-1.54 | $3.28 | ||
| Q1 25 | $-1.22 | $0.63 | ||
| Q4 24 | $-11.75 | $0.82 | ||
| Q3 24 | $-0.63 | $0.70 | ||
| Q2 24 | $-0.02 | $-0.06 | ||
| Q1 24 | $0.44 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.4M | $155.0M |
| 总债务越低越好 | $117.6M | $52.5M |
| 股东权益账面价值 | $715.8M | $391.5M |
| 总资产 | $2.2B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.16× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资OSGRIGL
| Q4 25 | $146.4M | $155.0M | ||
| Q3 25 | $27.5M | $137.1M | ||
| Q2 25 | $22.5M | $108.4M | ||
| Q1 25 | $34.1M | $77.1M | ||
| Q4 24 | $157.2M | $77.3M | ||
| Q3 24 | $40.8M | $61.1M | ||
| Q2 24 | $14.6M | $49.1M | ||
| Q1 24 | $13.8M | $49.5M |
总债务OSGRIGL
| Q4 25 | $117.6M | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $0 | $60.0M | ||
| Q3 24 | $518.0M | $60.0M | ||
| Q2 24 | $515.0M | $60.0M | ||
| Q1 24 | $512.0M | $60.0M |
股东权益OSGRIGL
| Q4 25 | $715.8M | $391.5M | ||
| Q3 25 | $843.4M | $117.6M | ||
| Q2 25 | $859.8M | $81.9M | ||
| Q1 25 | $852.2M | $18.6M | ||
| Q4 24 | $798.4M | $3.3M | ||
| Q3 24 | $1.5B | $-14.6M | ||
| Q2 24 | $1.4B | $-29.9M | ||
| Q1 24 | $1.4B | $-31.7M |
总资产OSGRIGL
| Q4 25 | $2.2B | $513.6M | ||
| Q3 25 | $2.1B | $242.5M | ||
| Q2 25 | $8.5B | $206.7M | ||
| Q1 25 | $8.3B | $176.0M | ||
| Q4 24 | $8.1B | $164.0M | ||
| Q3 24 | $9.3B | $139.4M | ||
| Q2 24 | $8.2B | $128.4M | ||
| Q1 24 | $8.4B | $126.5M |
负债/权益比OSGRIGL
| Q4 25 | 0.16× | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.00× | 18.25× | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.38× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.3M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流OSGRIGL
| Q4 25 | $-52.3M | $22.0M | ||
| Q3 25 | $-41.2M | $24.0M | ||
| Q2 25 | $2.1M | $30.5M | ||
| Q1 25 | $-12.6M | $-893.0K | ||
| Q4 24 | $762.0K | $14.5M | ||
| Q3 24 | $48.9M | $21.7M | ||
| Q2 24 | $20.4M | $302.0K | ||
| Q1 24 | $7.1M | $-5.0M |
现金转化率OSGRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.34× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OSG
| Other | $28.7M | 43% |
| Specialty Property Casualty Program | $23.1M | 34% |
| Accident Health | $9.6M | 14% |
| Specialty Automobile | $3.1M | 5% |
| Niche Specialty Risks | $2.4M | 4% |
RIGL
暂无分部数据
